2015 Graft Sources and Manipulation
Total Page:16
File Type:pdf, Size:1020Kb
Not for publication or presentation A G E N D A CIBMTR WORKING COMMITTEE FOR GRAFT SOURCES & MANIPULATION San Diego, CA Thursday, February 12, 2015, 12:15 – 2:15 pm Co-Chair: Daniel Fowler, MD, NIH-NCI Experimental Transplantation and Immunology Branch, Bethesda, MD; Telephone: 301-435-8641; Fax: 301-480-4354; E-mail: [email protected] Co-Chair: Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, New York NY; Telephone: 212-639-8682; Fax: 212-717-3500; E-mail: [email protected] Co-Chair: Vanderson Rocha, MD, PhD, Churchill Hospital, Oxford, United Kingdom; Telephone: 44 1865 572326; Fax: 44 1865 235260; E-mail: [email protected] Statisticians: Mei-Jie Zhang, PhD, CIBMTR Statistical Center, Milwaukee, WI; Telephone: 414-456-8375; Fax: 414-456-6513; E-mail: [email protected] Junfang Chen, MS, CIBMTR Statistical Center, Milwaukee, WI; Telephone: 414-805-0711; Fax: 414-805-0714; E-mail: [email protected] Scientific Director: Mary Eapen, MBBS, MS, CIBMTR Statistical Center, Milwaukee, WI; Telephone: 414-805-0700: Fax: 414-805-0714; E-mail: [email protected] 1. Introduction a. Minutes and Overview Plan from February 2014 meeting (Attachment 1) b. Introduction of incoming Co-Chair: Asad Bashey, MD, PhD; The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA. Email: [email protected] 2. Accrual Summary (Attachment 2) 3. Presentations, published or submitted papers a. GS05-01 Karen K. Ballen, Brent R. Logan, Mary J. Laughlin, Wensheng He, Daniel R. Ambruso, Susan E. Armitage, Rachel L. Beddard, Deepika Bhatla, William Y.K. Hwang, Joseph E. Kiss, Gesine Koegler, Joanne Kurtzberg, Arnon Nagler, David Oh, Lawrence D. Petz, Thomas H. Price, Ralph R. Quinones, Voravit Ratanatharathorn, J. Douglas Rizzo, Kathleen Sazama, Andromachi Scaradavou, Michael W. Schuster, Leonard S. Sender, Elizabeth J. Shpall, Stephen R. Spellman, Millicent Sutton, Lee Ann Weitekamp, John R. Wingard, Mary Eapen. Effect of Cord Blood Processing on Transplant Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant, In press, 2015. b. GS08-01 Craig Kollman, Stephen R. Spellman, Mei-Jie Zhang, Anna Hassebroek, Claudio Anasetti, Joseph H. Antin, Richard E. Champlin, Dennis Confer, John DiPersio, Marcelo Fernandez-Vina, Robert Hartzman, Mary M Horowitz, Carolyn K Hurley, Chatchada Karanes, Martin Maiers, Carlheinz Mueller, Michelle Setterholm, Ann Woolfrey, Neng Yu, Mary Eapen. The Effect of Donor Characteristics on Survival after Unrelated Donor Transplantation for Hematologic Malignancy. Submitted. 1 Not for publication or presentation c. GS13-01 Doris M. Ponce, Rodney Sparapani, Junfang Chen, Vanderson Rocha, Daniel H. Fowler, Mary Eapen, Juliet N. Barker, Migule-Angel Perales. Comparable 3-Year Disease-Free Survival Regardless of Anti-Thymocyte Globulin Inclusion in Pediatric Myeloablative Cord Blood Transplantation for Acute Lymphoblastic Leukemia. Presented at the 56th annual meeting of the American Society of Hematology, San Francisco, CA, December 2014 (Poster presentation). d. SC11-02b Mary Eapen, Brent R. Logan, Fredrick R. Appelbaum, Joseph H. Antin, Claudio Anasetti, Daniel R. Couriel, Junfang Chen, Richard T. Maziarz, Philip L. McCarthy, Ryotaro Nakamura, Voravit Ratanatharathorn, Ravi Vij, Richard E. Champlin. Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. Biol Blood Marrow Transplant. 21(1): 55-59 2015. e. SC11-02a Mary Eapen, Brent R. Logan, Mary M. Horowitz, Xiaobo Zhong, Miguel Angel Perales, Stephanie J. Lee, Vanderson Rocha, Robert J. Soiffer, Richard E. Champlin. Bone Marrow or Peripheral Blood for Reduced Intensity Conditioning Unrelated Donor Transplantation. J Clin Oncol. In press, 2014. f. GS12-01 Johan Törlén, Olle Ringdén, Jennifer Le Rademacher, Minoo Batiwalla, Junfang Chen, Tom Erkers, Vincent Ho, Partow Kebriaei, Carolyn Keever-Taylor, Tamila Kindwall-Keller, Hillard M. Lazarus, Mary J. Laughlin, Michael Lill, Tracey O’Brien, Miguel-Angel Perales, Vanderson Rocha, Bipin N. Savani, David Szwajcer, David Valcarcel, Mary Eapen. Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 20 (9): 1418-1425 2014. g. GS12-03 Daniel Weisdorf, Mary Eapen, Annalisa Ruggeri, Mei-Jie Zhang, Xiaobo Zhong, Claudio Brunstein, Celalettin Ustun, Vanderson Rocha, Eliane Gluckman. Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: a Center for International Blood and Marrow Transplant Research-Eurocord Analysis. Biol Blood Marrow Transplant 20 (6): 816- 822 2014. h. GS14-01a Stefan Ciurea, Mei-Jie Zhang, Andrea Bacigalupo, Asad Bashey, Fredrick Appelbaum, Philippe Armand, Joseph Antin, Omar Altijwa, Junfang Chen, Steve Devine, Daniel Fowler, Ryotaro Nakamura, Miguel-Angel Perales, Ravi Pingali, David Porter, Marcie Riches, Olle Ringden, Vanderson Rocha, Ravi Vij, Daniel Weisdorf, Richard Champlin, Ephraim Fuchs, Mary Eapen. Survival after T-cell Replete Haplo-identical Related Donor Transplant with Post-transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. Presented at the 56th annual meeting of the American Society of Hematology, San Francisco, CA, December 2014 (Oral presentation). 4. Studies in progress (Attachment 3) a. GS13-02 Matching between UCB units in double CB HCT (C Brunstein) Protocol Development b. GS14-01a Haploidentical vs. matched unrelated HCT (S Ciurea/ O Ringden/E Manuscript Preparation Fuchs/A Bacigalupo) c. GS14-01b Haploidentical vs. CB HCT (A Mussetti /M Perales) Data File Preparation d. GS14-02 Association between recipient and donor sex and clinical Analysis outcomes after allogeneic HCT (P Armand/H Kim) 2 Not for publication or presentation 5. Future/proposed studies a. PROP 1410-01/1410-12/1411-26/1411-95/1412-12 Selecting the best Haplo-identical donor (Attachment 4) b. PROP 1411-98 DRI-guided Graft Source Selection for Allogeneic Hematopoietic Cell Transplantation in Adults with Leukemia and Lymphoma (N Bejanyan/D Weisdorf) (Attachment 5) c. PROP 1411-40 Likelihood of survival for patients with acute leukemia who are alive and disease-free at 3, 6, & 12 months post-transplant: Are there differences by donor source? (W Hwang) (Attachment 6) d. PROP 1412-03 What should be the minimum required stem cell dose for successful autologous peripheral blood HCT after myeloablative conditioning? (G Akpek) (Attachment 7) e. PROP 1412-24 What is the optimal stem cell source (peripheral blood versus bone marrow) for recipients aged ≥20 years with HLA-matched sibling donors? (George Chen) (Attachment 8) 6. Other Business 3 Not for publication or presentation Attachment 1 MINUTES AND OVERVIEW PLAN CIBMTR WORKING COMMITTEE FOR GRAFT SOURCES & MANIPULATION Grapevine, TX Thursday, February 27, 2014, 2:45-4:45 pm Co-Chair: Daniel H. Fowler, MD, National Cancer Institute, Bethesda, MD Telephone: 301-435-8641; Fax: 301-480-4354; E-mail: [email protected] Co-Chair: Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center, New York, NY Telephone: 212-639-8682; Fax: 212-717-3500; E-mail: [email protected] Co-Chair: Vanderson Rocha, MD, PhD; Churchill Hospital, Oxford, UK Telephone: 44-1865-572326; Fax: 44-1865-235260; E-mail: [email protected] Statisticians: Mei-Jie Zhang, PhD, CIBMTR Statistical Center, Milwaukee, WI Telephone: 414-955-8375; Fax: 414-955-6513; E-mail: [email protected] Junfang Chen, MS, CIBMTR Statistical Center, Milwaukee, WI Telephone: 414-805-0711; Fax: 414-805-0714; E-mail: [email protected] Scientific Director: Mary Eapen, MD, MS, Medical College of Wisconsin, Milwaukee, WI Telephone: 414-805-0700; Fax: 414-805-0714; E-mail: [email protected] 1. Introduction Dr. Fowler opened the meeting at 2:45 pm by welcoming the working committee members for attending the Graft Sources and Manipulation working committee (GSWC). He then briefly introduced the GSWC’s leadership, goals, expectations and limitations. He also presented the voting process, rule of membership/ authorship, and working committee evaluation information. The minutes of the February 2013 meeting were approved as written. Members were referred to the accrual summary, which reflects potentially eligible cases when considering submitting study proposals to this committee. 2. Published papers Dr. Perales reviewed publications (shown below), and summarized the findings and conclusions of on-going studies described below. There were two presentations at the 2013 American Society of Hematology meetings and one, at the 2013 European Group for Blood and Marrow Transplantation meeting. a. GS08-02 Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood 121(13):2567-73, 2013. b. GS09-02 Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, Arcese W, Barker JN, Baxter-Lowe LA, Brown M, Fernandez-Vina MA, Freeman J, He W, Iori AP, Horowitz MM, 4 Not for publication or presentation Attachment 1 Locatelli F, Marino S, Maiers M, Michel G, Sanz GF, Gluckman E, Rocha V. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood